Erasca, Inc.

Contributing Author

Recent Articles by Erasca, Inc.

Aug-24	Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma ERAS GlobeNewswire
Aug-11	Erasca Reports Second Quarter 2026 Business Updates and Financial Results ERAS GlobeNewswire
Aug-10	Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ERAS GlobeNewswire
Aug-10	Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D ERAS GlobeNewswire
Jul-15	Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares ERAS +9.03% ERAS -10.54% GlobeNewswire
Jul-13	Erasca Announces Pricing of Upsized Public Offering of Common Stock ERAS +8.94% GlobeNewswire
Jul-13	Erasca Announces Proposed Public Offering of $500 Million of Common Stock ERAS ERAS +8.94% GlobeNewswire
Jul-13	Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors ERAS ERAS +8.94% GlobeNewswire
May-27	Erasca to Present at the Jefferies Global Healthcare Conference ERAS +8.43% GlobeNewswire
May-11	Erasca Reports First Quarter 2026 Business Updates and Financial Results ERAS GlobeNewswire
May-11	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA (Pembrolizumab) ERAS GlobeNewswire
May-06	Erasca to Present at the Bank of America Securities Health Care Conference ERAS +9.11% GlobeNewswire
Apr-27	Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors ERAS -10.89% ERAS -48.30% GlobeNewswire
Apr-27	Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 ERAS -10.89% GlobeNewswire
Mar-12	Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results ERAS -5.48% ERAS -7.03% GlobeNewswire
Mar-10	Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau ERAS GlobeNewswire
Mar-05	Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat ERAS GlobeNewswire
Feb-24	Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 ERAS GlobeNewswire
Feb-05	Erasca to Present at Upcoming Conferences in February ERAS +5.69% GlobeNewswire
Jan-23	Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares ERAS GlobeNewswire
Jan-21	Erasca Announces Pricing of Upsized Public Offering of Common Stock ERAS GlobeNewswire
Jan-20	Erasca Announces Proposed Public Offering of $150 Million of Common Stock ERAS GlobeNewswire
Jan-12	Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones ERAS -7.84% GlobeNewswire
Jan-06	Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference ERAS GlobeNewswire
Nov-25	Erasca to Present at the 8th Annual Evercore Healthcare Conference ERAS +6.23% GlobeNewswire
Nov-12	Erasca Reports Third Quarter 2025 Business Updates and Financial Results ERAS +12.29% GlobeNewswire
Nov-06	Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 ERAS GlobeNewswire
Nov-04	Erasca to Present at Upcoming Conferences in November ERAS GlobeNewswire
Sep-02	Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference ERAS GlobeNewswire
Aug-12	Erasca Reports Second Quarter 2025 Business Updates and Financial Results ERAS +5.41% GlobeNewswire
Jun-02	Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 ERAS GlobeNewswire
May-29	Erasca to Present at Upcoming Investor Conferences in June ERAS +31.82% GlobeNewswire
May-13	Erasca Reports First Quarter 2025 Business Updates and Financial Results ERAS GlobeNewswire
May-13	Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway ERAS GlobeNewswire
May-07	Erasca to Present at the Bank of America Securities Health Care Conference ERAS GlobeNewswire

Erasca, Inc.

Recent Articles by Erasca, Inc.

Upgrade your Finviz experience